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IMMUNE RESPONSE IN NEUROCYSTICERCOSIS: 
SOLITARY VERSUS MULTIPLE NEUROCYSTICERCOSIS
INTRODUCTION
Neurocysticercosis  (NCC)  is  caused  by  the  larval  stage  of  the  pork 
tapeworm,  Taenia solium and is  a  major  public  health  problem,  especially  in 
developing  countries  where  it  is  endemic.  It  is  the  most  common  parasitic 
infection  of  the  central  nervous  system  (CNS)  and  cause  of  symptomatic 
seizures (late onset seizures) in the disease endemic countries, causing major 
morbidity and mortality.
T solium infections are those of antiquity. Tapeworms and their treatment 
were  discussed  in  ancient  Egypt  and  possibly  referred  to  in  ancient  Indian 
literature.  The  earliest  description  of  cysticercosis  are  that  of  vesicles  in  the 
corpus  callosum  by  Paranolus  in  1550.  Taenia  solium infection  causes  two 
diseases in humans, “Taeniasis”, the intestinal infection with the tapeworm and 
“Cysticercosis”, the larval infection of the tissues. The serious T solium infections 
are those of the central nervous system and of the eye.
Poor  sanitation  and  animal  husbandry  practices  are  found  to  be  risk 
factors  for  NCC.  Risk  factors  for  neurocysticercosis  of  poor  sanitation,  free 
roaming  pigs  and  non-regulated  sale  of  pork,  exist  in  all  countries  where  T 
solium infections prevail.  Yet  in South and Latin America, Sub-Saharan Africa 
and  most  countries  of  South  East  Asia,  NCC  is  predominantly  a  multi  cyst 
infection while in India NCC is mainly a solitary cyst infection.   It is not clear why 
the magnitudes of infection are so different.
T solium eggs ingested by man, release hexacanth embryos in intestine, 
which  through circulation  reaches target  organs resulting  in  cysticercosis.   T 
solium ova  density  in  the  environment  is  one  of  the  factors  suggested  in 
determining cyst numbers in NCC.  Low ova densities are associated with less 
ova ingestion and the development of solitary cyst NCC. In environments highly 
contaminated with  T solium ova the probability  of  ingesting large numbers of 
eggs is high and would result in multi-cyst disease.  In India, even though the 
frequency  of  pork  consumption  is  less  than  most  endemic  countries,  the 
prevalence of  Taeniasis is comparable to other endemic countries; yet solitary 
cyst disease is more common than multiple cyst disease in India. 
It is possible that cyst load in NCC is influenced by host immunity. The 
number of exposures, genetic factors, host-parasite immune response and the 
presence of co-infections could modify the immune response and play a role in 
determining the outcome. In Taenia infections the host determines the severity of 
disease, resistance to and pathogenesis of NCC. The innate immune response 
induced in early interactions between parasite antigens and immune cells of the 
host is important in determining whether parasite oncospheres will be cleared or 
permitted  to  establish  cyst  infection.  The  subsequent  host  cellular  immune 
response would be important in determining the course of the infection as well as 
in clearance of the cyst.
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It  has been shown in animals that immunity against helminth infections 
requires the induction of  a Th1 /  pro-inflammatory response while infection is 
established by induction of a Th2 / anti-inflammatory cytokine response in the 
host.   The cellular  immune response has not  been clearly  defined in  human 
Taenia infections especially neurocysticercosis but may also impact on disease 
profile. 
To  explore  the  influence of  host  cellular  immunity  and cyst  number  in 
Indian patients with NCC, the response of peripheral blood mononuclear cells 
(PBMCs)  to  infection  specific  T  solium glycoprotein  antigens  was  compared 
between  healthy  young  adults  and  patients  with  multi-cyst  and  solitary  cyst 
infections.  The  immune  response  to  N-glycans  of  the  infecting  T  solium 
glycoproteins was also studied in view of their critical importance for cysticercus 
antibody recognition. Interleukin-12(IL-12) was measured as a marker of the Th1 
response and interleukin-4 (IL-4)  of  Th2 response. The possible role of  nitric 
oxide in protecting the host against infection and thus contributing to magnitude 
of cyst load was also examined.
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AIMS AND OBJECTIVES OF THE STUDY
AIM: 
To determine the role of host cellular immunity in the prevalence of Taenia 
solium solitary cyst infections in India.
OBJECTIVES:
1. To  study  the  Th1  and  Th2  cytokine  response  of  peripheral  blood 
mononuclear  cells,  from patients  with  solitary  NCC,  multiple  NCC and 
from  healthy  controls,  stimulated  with  T  solium infection  specific 
glycoprotein antigens.
2. To study the nitric oxide response of peripheral blood mononuclear cells, 
stimulated with T solium infection specific glycoproteins to understand the 
role of macrophages in protecting the host against T solium cysticercosis.
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REVIEW OF LITERATURE
Biological cycle and characteristics of Taenia solium
The pork tapeworm  Taenia solium belong to  the family  Taenidae.  The 
family  Taenidae has 11 genera of small to large sized tapeworms. The genus 
Taenia has about 20 species that in addition to T solium (pork tapeworm) include 
T saginata (beef tapeworm),  T crassiceps  (rodent tapeworm),  T hydatigena,  T 
ovis and  T pisiformis (canine tapeworm).   Among  Taenidae,  the species that 
pose  health  problems  to  humans  are  T  solium,  T  saginata,  Echinococcus 
granulosus and E multilocularis.1
The  life  cycle  of  the  cestode  T  solium involves  two  stages:  the  adult 
tapeworm,  living  in  the  human  small  intestine,  and  the  larvae  or  cysticerci, 
usually located in the muscle of pigs. Humans can be the definitive (intestinal 
worm, sexual cycle) host or intermediate (neurocysticercosis, asexual cycle) host 
or both for  T solium. There is generally one single adult worm, however, there 
may be several, particularly in cases of habitual ingestion of raw pork meat as 
seen in some endemic communities.
The adult worm (Fig.1) presents a flat, tape-like shape, reaching as much 
as eight meters in length. T solium is a hermaphrodite. It has no celomic cavity or 
digestive  apparatus,  and  nutrition  occurs  through  the  surface.  The  excretory 
system  is  made  of  two  channels  located  sideways  and  lengthwise  on  the 
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proglottids, connecting to those in the next proglottid and open to the outside in 
the  last  proglottid.  The  genital  pores  are  located  on  the  side  edge  of  each 
proglottid, at medium height.
Three portions can be observed: head, neck and body or strobile.
Head or scolex: It is globular in shape, 1 mm in diameter. It has a rostellum, with 
a double crown of hooks, arranged alternately. It also has four ventoses, being 
hooks and ventoses its fixation organs to adhere to the intestinal mucosa.(Fig.2)
Neck:  Short  and thin,  measuring 5 to  10 mm long,  it  is  the portion with  the 
highest biosynthetic activity, because the formation of the immature proglottids 
starts off at the neck. 
Body  or  strobile: It  is  the  longest  portion  of  the  parasite  and  is  made  of 
hundreds of proglottids or rings of the following kinds:
Immature Proglottids: Their transversal diameter is longer than the longitudinal 
one. An incipient genital apparatus can be observed.
Mature Proglottids: Square in shape, follow the immature ones. The female 
genital  apparatus can be seen with  a trilobulated ovary,  and the male genital 
apparatus with over 100 testicular masses.
Gravid Proglottids:  They are rectangular in shape, with a slightly predominant 
longitudinal diameter. Most of the male and female genitalia are atrophic, and 
only the uterus can be seen with 30,000 to 50,000 eggs. The uterus is branched 
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with an axis alongside the proglottid.  It has up to 12 primary branches coming 
out of it, and smaller dendritic ramifications arising from the primary branches.2
Tapeworm 
Adult Worm 
Fig.1: Adult Worm
Scolex
Fig.2: Scolex
Source: CDC – Division of Parasitic Diseases.
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Physiology:
T  solium has  no  digestive  tract.  Food  is  obtained  from  the  intestine 
through the body surface, which has microvilli that increase the parasite’s surface 
and enhance the metabolic exchange between the tapeworm and the intestinal 
environment. Excretion products are eliminated through excretory tubes whose 
openings are located in the last gravid proglottid of the strobile.2
The  excretory/secretory  products  eliminated  by  the  tapeworm  to  the 
outside, along with the feces, are useful because they contain antigenic fractions 
(coproantigens)  used for  immunodiagnosis  through the preparation of  specific 
antibodies and their use in highly sensitive techniques, such as ELISA (Enzyme-
Linked ImmunoSorbent Assay).3 
Life cycle: (Fig.3)
Man is the sole definite host for the adult taenia, and the pig is the usual 
intermediary host for the larval  stage. Man can be an accidental  intermediary 
host.
Ingestion  of  raw or  undercooked pork  infested  with  cysticerci  leads to 
Taeniasis. Ingested cysticerci are activated in gastric juice, attach to the mucosa 
of the small intestine, and develop into adult tapeworms. The worm elongates by 
strobilization,  which  is  a  formation  of  a  string  of  proglottids.  The  proglottids 
mature and become gravid. The terminal, gravid proglottids break off from the 
adult tapeworm and are excreted in feces. 
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The eggs, eliminated free or inside gravid proglottids in the feces of the 
individual infected with  T solium adult tapeworm, contain a hexacanth embryo 
presenting with six hooks. The eggs are morphologically undistinguishable from 
those  of  T  saginata, making  the  differentiation  difficult.  The  development  of 
fluoresceine-conjugated  specific  antibodies  against  T  solium eggs  helps  in 
species identification. When ingested by the pig, eggs are submitted to the action 
of the digestive solutions, and release the hexacanth embryos that adhere to the 
mucosae and then penetrate the intestinal walls reaching blood vessels and are 
transported to various organs and tissues, including muscle, eye and brain.
Humans complete the life cycle of  T solium by ingesting infected pork. 
From  an  evolutionary  standpoint,  the  location  of  cysticerci  in  pig  muscle  is 
important, since it permits the completion of the life cycle. Humans like pigs, can 
become  intermediate  hosts  if  fresh  vegetables,  uncooked  food,  or  water 
contaminated with human feces is ingested.
The cysticercus is the larval stage of T solium, called Cysticercus cellulose 
by Rudolphi in 1803 given its predilection for conjunctive tissue. The morphology 
of  cysticercus  is  generally  that  of  a  vesicle,  but  at  times,  in  the  brain,  this 
morphology  can  vary  to  irregular  forms  (Racemose  form).  The  infection  by 
cysticerci is called Cysticercosis, human or porcine.2
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Fig.3: Life cycle of T solium
Source: Clinical Microbiology Reviews, Oct 2002.4
Human cysticercosis 
Man can ingest T solium eggs in contaminated food. Contact with  taenia 
infected individuals is believed to be the most probable mechanism for infection 
along with poor hygienic habits allowing for the contamination of hands by eggs, 
and thus the likelihood of contaminating the food for the family group. Also, eggs 
that contaminate short-stem vegetables and/or water for consumption can also 
be ingested, particularly in areas with poor environmental sanitation and open air 
defecation.
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It  is  also  claimed  that  intestinal  retroperistaltic  movements  induced  in 
taenia carriers by any cause, such as vomiting, would allow for eggs to reach 
stomach, and here, the action of gastric fluids on the proglottids or egg surface 
may permit  the  release  of  the  hexacanth  embryos,  their  penetration  into  the 
intestinal  mucosa  and  the  completion  of  the  known  course,  thus  causing  an 
“internal autoinfection”. This possibility would substantiate the presence of 6% of 
Taeniasis in individuals who are currently infected with cysticercosis.
The location of cysticerci in human tissue varies from the subcutaneous 
location,  which  is  relatively  benign,  to  ocular  and  central  nervous  system 
locations, with a malignant evolution.2
Neurocysticercosis
T solium infections of the central nervous system and of the eye are the 
most serious forms of the cysticercosis in humans that are associated with high 
morbidity and mortality.  Clinical manifestations of neurocysticercosis are highly 
variable depending upon the number, location and the evolutionary stage of the 
cysts.3  The most common manifestation of neurocysticercosis is seizures, focal 
or  generalized,  which  manifest  when  cysts  degenerate  in  the  brain  causing 
intense inflammatory response by the host.
T solium infections  are  the  most  common parasitic  infestations  of  the 
central nervous system and cause of recent onset seizures in countries endemic 
for the infection. Epilepsy affects 5 million people in India and is the second most 
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common  chronic  neurological  condition  in  the  country.  Here  one  in  three 
epileptics between the ages of 2 and 60 years have seizures due to NCC.5,6,7,8
In most endemic countries NCC is mainly a multi-cyst disease (MNCC), 
whereas  in  India,  solitary  cysticercus  granuloma  (SCG)  is  the  common 
presentation.9 
Hospital data from different parts of the country indicate that more than 
60% of NCC patients present with a single cyst lesion and one third with 2 or 
more  cysts.9,10,11 This  is  interesting  because  with  similar  risk  factors  in  other 
endemic countries in South America and Africa, MNCC is more prevalent than 
SCG. 
In South America the prevalence of Taeniasis is reported to reach 6% in 
the  population,  while  porcine  cysticercosis  can  be  as  high  as  30%.  The 
prevalence of taeniasis in the general population in India is reported to be 0.1 – 
6%12 and  18.6%  in  certain  pockets13 whereas  the  prevalence  of  porcine 
cysticercosis is reported to be 10-26%.14  These prevalence rates although less 
than South America,15 are not  that  low given the magnitude of  T solium egg 
production. Therefore in addition to prevalence levels of taeniasis, other factors 
that may contribute to NCC disease profile in India like host immunity which is 
discussed later. 
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Pathogenesis – pathological stages
After entering the central nervous system, the live cysticerci induce little 
local inflammatory changes but usually grow in size. Cysticerci secrete a serine 
protease  inhibitor  called  “taeniastatin”,  which  inhibits  leukocyte  migration, 
complement activation, and cytokine release. At this stage, called the vesicular 
stage, the cystic vesicles, round or slightly oval in shape, with translucid walls 
and diameters ranging from 0.5 to 1.5 cm, contain clear vesicular fluid.  It also 
contains a larva or scolex, which can be seen as a small eccentric solid granule. 
The cysticercus is surrounded by a thin layer of fibrous tissue that separates it 
from the surrounding tissue. Electron microscopy shows microvilli in its surface. 
Racemose cysticercus variety looks like a large, lobulated vesicle, similar to a 
bunch of grapes. It may measure up to 10 cm and contain several milliliters of 
fluid. It is generally observed in ventricular cavities and in the cisterns located on 
the base of the cranium. Scolex can be demonstrated histologically only in such 
cysts.
Following cysticidal  treatment  or  successful  immune response,  the first 
sign of involution of the cysticerci is the colloidal stage, in which a viscous and 
turbid fluid replaces the transparent fluid and the scolex dies. Colloidal cysticerci 
are  surrounded  by  a  thick  collagen  capsule,  astrocytic  gliosis,  edema  and 
neuronal  degeneration.  The  scolex  in  the  cyst  is  transformed  into  coarse 
mineralized  granules  –  the  granular-nodular  stage.  Finally  the  dead cyst  is 
replaced by focal fibrosis and mineralization – the calcific stage.16
17
Meningeal cysticerci in particular elicit an intense inflammatory reaction in 
the  subarachnoid  space,  forming  exudates  composed  of  lymphocytes, 
eosinophils, hyalinized parasite debris, and collagen fibers. This may result in 
obstruction  of  the  CSF  pathways  causing  hydrocephalus.  Small  penetrating 
arteries  arising  from  the  circle  of  Willis  are  frequently  affected  by  the 
subarachnoid inflammatory reaction, which may cause occlusion of the vessel 
and cerebral infarctions. Ventricular cysticerci attached to the choroid plexus or 
ventricular wall also cause an intense inflammatory reaction, resulting in granular 
ependymitis and hydrocephalus. Immunocompromised states may cause heavy 
parasitism or activation of dormant cysts.
Neurocysticercosis: Classification
Neurocysticercosis is classified according to anatomic location as well as 
by developmental stage of the cyst. 
The anatomical classification 
i) Parenchymal NCC: Presents with seizures, space occupying effects 
and intracranial hypertension with breach of the blood brain barrier.17,18 
ii) Subarachnoid  NCC: Presents  with  meningitis,  space  occupying 
effects and hydrocephalus.19 
iii) Ventricular NCC: Presents with acute hydrocephalus and meningitis. 
iv) Spinal NCC: NCC can also locate in the spine.20 
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The influence of anatomic location on developmental outcome of cysts is 
also seen between the brain and muscle. Cysts in the immunologically privileged 
brain remain vesicular for longer periods than those in the muscle.21
Classification based on stage of the cyst 
i) Active  NCC: Viable  cysts  that  do  not  produce  symptoms  and 
transitional forms when degenerating cysts produce acute symptoms
ii) Inactive NCC: Calcified cysts.21,22
Epidemiology
T solium infections are those of antiquity. Tapeworms and their treatment 
were  discussed  in  ancient  Egypt  and  possibly  referred  to  in  ancient  Indian 
literature.  The  earliest  description  of  cysticercosis  are  that  of  vesicles  in  the 
corpus callosum by Paranolus in 1550.23 The modern biology of T solium began 
in Europe in the 1600’s although it was only around 1850 that the link between 
the adult tapeworm and cysts were established, in ethically controversial studies, 
by Fredrich Kuchenmeister in Germany. He fed convicts awaiting execution with 
infected pork and in the autopsies performed after execution he detected growing 
and adult worms in the intestines of his subjects.24 
The association of  seizures and neurocysticercosis was documented in 
1862  by  the  German  psychiatrist  Griesenger.  In  1911  Vosgein  described 
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cysticercosis in 807 people, most of them French soldiers who had lived in the 
colonies. Between 1930 and 1960 seminal studies on cysticercosis and seizures 
in British soldiers returning from India were reported by MacArthur, Dixon and 
Lipscomb.25 - 27 This knowledge of cysticercosis has benefited from both the penal 
system and colonialism.
The indication that  T solium infections are prevalent in large parts of the 
world  emerged  from  epidemiological  studies  in  the  last  twenty  years,  when 
radiological  neuro-imaging  and  serological  tests  for  cysticercosis  became 
available.28-30  T solium infections are the most common parasitic infestation of the 
CNS in endemic countries. They are considered re-emerging infections of public 
health magnitude and importance. 
A brief  overview of the epidemiology of  human cysticercosis  follows in 
which the prevalence of cysticercosis is taken to reflect levels of NCC that might 
exist in the regions studied.
Cysticercosis  is  endemic  in  some  parts  of  all  continents  except  for 
Australia and Antarctica. It is endemic to South, Central and Latin America, Sub-
Saharan Africa and East and South Asia. In these areas, the disease accounts 
for up to 12% of all admissions to neurological hospital services and is the most 
common cause of acquired epilepsy in adults.31  It is also seen in industrialized 
world as immigration from endemic countries rises. 
Risk factors for transmission of cysticercosis in all countries include free 
roaming  pigs,  poor  sanitation  and  a  warm  humid  climate  that  permits  egg 
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survival.32-35  Human  cysticercosis  occurs  where  porcine  cysticercosis  is 
significant. In addition to these common risk factors there may be conditions that 
are specific to a country which contribute to the infection. These may include 
frequency  of  pork  consumption  in  different  populations,  culinary  habits 
(undercooking of meat, consumption of raw meat) and feeding patterns of free 
roaming pigs, as when pigs are fed human feces. 
Country specific risk factors pertaining to India may include pig rearers 
who  live  together  in  specified  areas  of  a  village  and  form  nodes  for  the 
transmission of infection.36  In support of this are studies by Prasad et al13 who 
found a high prevalence of Taeniasis among pig rearers (18.6%) in North India. 
Regions in endemic areas that are cysticercosis free are associated with a lack 
of pig industry, no pork consumption and / or good sanitation.37
The epidemiology of cysticercosis has been well studied in most countries 
of South and Central America and in Mexico. Seizures are associated with NCC 
in  all  these countries and it  is  the most  common cause of  recently  acquired 
seizures. Young adults among all ages are the most infected. Increased infection 
levels seen with age are surmised to result from re-infections because of high 
levels of the parasite in the environment.5,38
As  among  the  other  countries  of  the  Americas,  Mexico  has  a  high 
frequency  of  T  solium infections.  Approximately,  10%  of  the  population  in 
endemic  areas  is  seropositive  for  cysticercus  antibodies.39 Epidemiological 
studies  also  indicate  the  importance  of  clinically  silent  NCC  in  Mexico. 
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Asymptomatic NCC, evidenced by calcified cysts on neuro-imaging, occurred in 
9.1% of rural Mexico. Not all cases were seropositive nor did they correlate with 
exposure factors.40 Prevalence rates of NCC therefore need to be viewed with 
caution as under reporting may occur.
T  solium infections  are  equally  prevalent  in  Central  America.  In  rural 
Honduras  NCC  accounted  for  37%  of  epilepsy  cases  while  6.4%  of  the 
population  had  CT  findings  suggestive  of  NCC.41  Seroprevalence  for 
cysticercosis in Guatemala was as high as 17% in the rural population.42  In a 
study from Ecuador 2.25% of a rural population were found to be infected with T 
solium while  at  least  43% of  this  population  was  seropositive  for  cysticercus 
antibodies which indicates high exposure to the parasite.43
Although  food  habits  differ  across  Brazil,  the  largest  country  in  South 
America  where  raw  or  undercooked  pork  sausages  are  often  eaten.44 It  is 
therefore not surprising that NCC is endemic in Brazil  and accounts for up to 
13%  of  neurological  admissions  to  hospital.  Over  a  quarter  (27.8%)  of  all 
cysticercosis patients are elderly.45  It is mandatory to test for NCC in epileptics in 
Brazil  as  16%  of  them  are  considered  to  have  NCC.46 Seroprevalence  of 
cysticercosis in the general population is estimated to range from 0.87 to 6.22% 
in the different states.47
Comprehensive  epidemiology from Peru  indicates  the  country  is  hyper 
endemic for cysticercosis and the cause for 20-30% of adult onset seizures.48 
Seroprevalence  in  the  Peruvian  Highlands,  determined  by  immunoblots  for 
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cysticercus antibodies, ranged from 7.1 to 26.9% in a background of 42 to 75% 
porcine  cysticercosis.  A  similar  prevalence of  24.2% prevailed  in  the  coastal 
regions.49 Clustering of seropositive individuals in households as well as around 
tapeworm carriers are important aspects of infection in Peru.50  This phenomenon 
has been noted in Mexico as well.38
In  Venezuela  seroprevalence  of  cysticercus  antibodies  ranged  from 
4-36.5% in rural communities while active infections were apparent in 5.7-9.1% 
of these populations.51  In countries of Africa where epidemiology of cysticercosis 
has been studied, the prevalence of  T solium cysticercosis is high and a major 
cause of epilepsy. It is likely that cysticercosis will rise in Africa as the porcine 
population in most of Sub-Saharan Africa is large, on the increase and since pork 
is a significant component of the diet.52
In Western Cameroon (West Africa) where Taeniasis occurred in 0.13% of 
the population and cysticercosis  in  11% of  pigs,  3% of  the populations were 
actively infected with  T solium of whom 59.1% had NCC.53   In other regions of 
Cameroon 1.2% of  epilepsy cases were  due to  active  infections of  T solium 
although specific antibodies to the parasite were present in 44.6% of epileptics.54 
In Togo and Benin the prevalence of cysticercosis in the population was noted to 
be 2.4% and 1.3% respectively.55
Central Africa is hyper endemic for cysticercosis.  T solium cysticercosis 
underlies the majority of epilepsy in Burundi. Active infection was found in 20% of 
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the seizure-free population but levels of infection are possibly higher as 32% of 
the population with seizures were positive for cysticercus antibodies.56
In Eastern and Southern Africa the prevalence of porcine cysticercosis is 
significant with more than 50% of pigs infected in some regions. High levels of 
porcine cysticercosis are associated with increased human NCC and although 
levels are not known, it is likely the prevalence of human cysticercosis is high in 
East and South Africa. This suggestion is supported by the estimated 34,662 
NCC-associated cases of epilepsy in Eastern Cape Province in 2004.57
Epidemiological  studies  show that  neurocysticercosis  is  endemic  in  all 
countries  of  Asia  where  risk  factors  for  the  infection  prevail.  In  China 
seroprevalence of cysticercus antibodies ranged from 3.97-16.4%.58,59  In South 
East Asia among the indigenous people of Papua in Indonesia 67% of epilepsy 
cases were due to NCC, a consequence of the import  of the disease among 
these tribes.60  In  Bali  13.5% of  epileptics  were  infected  with  T solium while 
12.5% of the populations were asymptomatic for cysticercosis but seropositive 
for  the  antibodies.61 Cysticercus  antibodies  were  present  in  2.2%  of  a  rural 
population  of  Malaysia.62  Active  cysticercosis  infection  affect  5.35%  of  a 
mountainous population of Vietnam and 0.06% of those on the coast while urban 
populations of Vietnam do not seem to be infected.63 
In  India  NCC  occurs  across  the  country  and  accounts  for  8-31%  of 
epilepsy cases among hospital patients. The prevalence of active epilepsy in the 
community was found to be 3.83/1000 people with one third of the epilepsies 
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suffering from NCC.64  Cysticercus antibodies were estimated to be present in 
17.3% of the population in North India with a higher prevalence (20%) in the rural 
population  compared to  urban populations  (8%).65   In  South  India  cysticercus 
antibodies were noted in 6.1% of the population.66
A  seroprevalence  of  nearly  16%  for  cysticercus  antibodies  in  Vellore 
district, TamilNadu, India, where one-third of all households have one or more 
members seropositive for the antibodies, is high and categorizes the district as 
hyper  endemic for  exposure  to  T solium.  The immunoblot  used in  this  study 
under-reports infections with a single cyst  (60% sensitive) suggesting that the 
prevalence in Vellore district may be higher than stated. This is important, as 
almost one-third  of  all  epilepsy in Vellore district  is  due to  NCC.67  The high 
seroprevalence among adults  of  the district  may reﬂect  the  known increased 
susceptibility to infection with age.39 
Prasad  et  al.,  2007,13 reported  a  prevalence  of  T solium Taeniasis  of 
18.6% in the study conducted in a rural pig farming community of North India; 
factors associated with  Taeniasis on multivariate analysis were age above 15 
years,  history  of  passage  of  taenia segments  in  stool,  undercooked  pork 
consumption and poor hand hygiene. 6.6% subjects with epilepsy were identiﬁed. 
The study showed alarmingly high rates of epilepsy and T solium Taeniasis in the 
study community.
Epidemiologic data suggest that  30−40% of  Taenia solium seropositive 
people become spontaneously negative without acquiring cysticercosis and only 
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one-third of Taenia solium seropositive individuals harbor cysts within the brain. 
Although false-positive results may explain some of these cases, they could also 
be clinically silent cysticercosis cases or people who spontaneously resolved or 
even avoided infestation. Evidence supporting these possibilities in human and 
animal cysticercosis has been published.45
IMMUNE RESPONSE IN TAENIA SOLIUM INFECTION
When a pathogen enters an immunologically competent organism, innate 
(nonspecific) and adaptive (specific) immunological responses of the host result 
in  the  destruction  of  the  pathogen  and/or  of  the  host.  The  protective  or 
pathogenic  effectiveness  of  the  innate  response  greatly  depends  on  the 
generation of a nonspecific inflammatory phenomenon locally in the surroundings 
of the pathogen. The adaptive immune response rests on a systemic, selective 
clonal proliferation of lymphoid cells and their differentiation to effector cells type 
Th1 or Th2 with the subsequent production of various cytokines and plasma cells 
with the production of specific antibodies.68 
The great diversity of clinical forms associated with neurocysticercosis in 
humans  suggests  its  origin  involves  a  complex  participation  of  the  immune 
system.  Epidemiological  studies  of  T  solium infections  indicate  that  the  cyst 
persists in humans for long periods of time, often for years, and a large percent 
of  infected  individuals  develop  antibodies  to  the  parasite  but  do  not  contract 
disease. The immunity the parasite elicits in humans is clearly important in the 
pathogenesis of infection.
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In mammalian hosts helminths typically induce a Th2 immune response of 
IL-4, IL-5, IL-10 and IL-13, IgE with expansion and mobilization of effector cells 
such  as  mast  cells,  eosinophils,  and  basophils.  They  also  down  modulate 
immune cells to hypo-responsive state. Alternatively activated macrophages are 
also  considered  to  suppress  inflammation  and  promote  the  Th2  response  in 
helminth infections. Thus in addition to molecular mimicry and self masking to 
evade  expulsion,  helminth  parasites  induce  an  anti-inflammatory,  hypo-
responsive  environment  that  permits  their  long  survival  in  hosts.  Immune 
modulation  orchestrated  by  helminths  is  greatly  dependent  on  the  structural 
complexity of their antigens especially glycosylation.69-73 
The immune response in cysticercosis can be divided into three phases. 
During the very early events after oncosphere ingestion, the immune reaction 
type  and  rate  will  determine  resistance  or  susceptibility  to  metacestodes 
establishment.  This  is  followed  by  a  long  lasting  immune  response  to  the 
presence of living parasites that actively evade destruction by the host immune 
system. Finally the parasite is destroyed by an inflammatory reaction, both in the 
natural evolution of the infections or following anti-parasitic treatment.2 
Humoral immune response
Ingestion  and  absorption  of  T  solium eggs  (invasive  embryos  / 
oncospheres) leads, in a few days, either to their destruction, mediated through 
host  complement  and  antibody,  or  their  establishment  in  host  tissue  and 
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differentiation  into  cysticerci  (metacestodes).  It  has  been  proved  for  several 
taenia species (ie.,  T Taeniaeformis,  T ovis, T hydatigena) that antibodies and 
complement are the protective components against the oncospheres.74  If  the 
immune response is elicited more slowly than the development of the immune 
evasion mechanisms exerted by the parasite, the metacestodes gets established 
making antibodies and complements no longer effective in destroying it. Thus, a 
competition between the establishment of the protective immunity by the host 
and the development of the evasion mechanisms by the parasite seems to occur 
during the initial days of infection (fig.4). 
Fig.4 
Studies  have  demonstrated  that  antibodies  are  protective  during 
oncosphere  invasion.  The humoral  response of  T solium cysticercosis  in  the 
early phase of  infection, driven by Th2 cytokines,  is  protective as it  prevents 
infection  by  complement  mediated  antibody  destruction  of  the  invasive 
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oncosphere.  It  is  shown  in  murine  T  taeniaeformis infections,  that  resistant 
strains  produce  specific  antibodies  earlier  than  susceptible  strains.75  These 
studies have led to  the development of  antigen vaccines that  protect  against 
infection in animal T solium cysticercosis.76-78
Antibody  production  also  occurs  during  active  infection  although  cysts 
themselves are resistant to antibody mediated destruction. Immunoglobulins coat 
the surface of the cyst and mask its antigens, which protects the parasite from 
the host.79  The antigenic complexity to  T solium leads to production of diverse 
immunoglobulins  several  of  which  are  specific  to  the  parasite.  Most  of  the 
immunoglobulins are of the IgG class and reflect the chronicity of infection. The 
humoral  response  in  T  solium cysticercosis  is  both  systemic  and 
compartmentalized  with  intrathecal  immunoglobulin  synthesis  occurring  in 
NCC.80-82
Immune evasion mechanism
Once established, the viable metacestode despite transformation from a 
30  micron  long  oncosphere  to  a  1cm  diameter  cyst,  elicit  minimal  or  no 
inflammatory reaction in host tissue due to their ability to evade host immunity. 
This  also  permits  their  survival  in  the  host  for  long periods  of  time.  Immune 
evasion strategies developed by  T solium metacestodes include masking their 
surface with host derived antibodies and complement factors, molecular mimicry 
by synthesizing proteins that resemble host molecules and secretion of factors 
that actively suppress cellular and humoral immune responses.83-86
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Nitric oxide
Resistance to  taenia infection is also associated with  induction of  nitric 
oxide from macrophage that destroys the parasite.  Mice susceptible to  taenia 
infections were found to control parasitemia through induction of nitric oxide while 
inhibition  of  inducible  nitric  oxide  synthase  in  macrophages  increases 
parasitemia.87,88
Cellular immune response
Dying  T solium cysts  degenerate  inducing  infiltration  and inflammatory 
reactions in surrounding tissue that lead to the granulomatous pathology of the 
infection.  Reactions  to  degenerating  cysts  in  the  brain  are  associated  with 
seizures. Predominant components of the inflammatory response include plasma 
cells, lymphocytes, eosinophils and macrophages. The degenerating parasite is 
phagocytosed by macrophages leaving a gliotic scar with calcification. Several 
correlative clinical,  neuro-imaging, immunological and histopathological studies 
have demonstrated that  symptomatic  human cycticercosis  corresponds to  the 
presence of tissue inflammation around involuting cysticerci  that are transiting 
between viable and calcified stages.75,89,90
In  T crassiceps, Th1 immune response is shown to be protective during 
the  early  phase  of  infection  and  switch  to  Th2  type  of  response  has  been 
documented to occur 2-3 weeks later that down regulates the Th1 response.91 
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The cellular immune response of cysticercosis has been examined in the 
CSF, blood and granuloma itself.92-94  In infected mice early granulomatous tissue 
expressed  Th1  cytokines  IL-2  and  IFN-γ  that  caused  parasite  destruction. 
Subsequent to parasite destruction, down regulation of inflammatory reactions 
may  occur  through  IL-4  that  is  detected  in  the  tissue.  The  cellular  immune 
response thus follows a temporal profile of Th1 in early pathology contributing to 
both pathogenesis of  infection and clearing of  the parasite that  changes to a 
mixed Th1 / Th2 response when parasite destruction is complete.95,96 
Viable cysts are associated with a Th2 response that is stimulated by the 
parasite.  It  is  surmised that  when  cysts  degenerate  they no  longer  have  the 
ability to direct the host to suppress Th1 immunity which is then activated and 
clears  the  parasite.  In  the  brain  the  degenerating  cyst  is  thought  to  activate 
microglia  and  resident  macrophages  to  produce  chemokines  that  attract 
monocytes and neutrophils across the blood brain barrier. This process initiates 
monocyte-astrocyte networks to further secrete chemokines that lead to influx of 
lymphocytes into the brain.97  The lymphocyte influx and chemokine secretion 
directs Th1 cytokines to induce larval degeneration and mount antigen-antibody 
immune responses. This inflammatory Th1 granulomatous response is possibly 
that  which  gives  rise to  the symptoms of  NCC.  As the cyst  is  destroyed the 
response  is  modulated  to  express  more  Th2 cytokines  to  down  regulate  the 
inflammation.98,99 
Immunosuppression  by  viable  cysts  is  a  prominent  feature  of 
cysticercosis. This immunosuppression is noted in brain tissue in the vicinity of 
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cysts, in the decrease of T and B cells in heavily infected pigs and anergy in mice 
of T cells in proximity to cysts.91,100,101 
In lymphoproliferative assays active peripheral cellular immune responses 
are noted in patients with NCC not on immunosuppressive corticosteroids, which 
decrease in  presence of high concentrations of  specific  taenia antigens.  This 
would  be  in  keeping  with  the  immune  suppression  properties  many  taenia 
antigens  possess.102,103  Suppressed peripheral  cellular  immune reactions  but 
increased levels of all  specific IgG subclasses are noted in symptomatic NCC 
patients whose cysts are located in the ventricles or in the subarachnoid space. 
Cyst  antigens  from  these  locations  drain  into  the  CSF and  serum  and  thus 
peripheral lymphocytes of these patients are exposed to high concentrations of 
taenia antigens.104 Peripheral  lymphocytes  from  asymptomatic  NCC  patients 
whose cysts are located in the parenchyma and are calcified are not exposed to 
high levels of taenia antigens and thus exhibit robust cellular immune reactions, 
predominantly of the Th2 type but low plasma levels of IgG. These studies were 
taken  to  indicate  that  a  Th2  immune  profile  favors  an  uneventful  course  of 
infection and protects against the parasite.105-107 
Protection was considered to develop in response to frequent contact with 
the parasite as may occur in endemic regions. In mice the Th2 cytokines IL-4 and 
IL-13 mediated host protection in taenia infections were found to require TNF-α 
for  modulation.  Taenia infections in  TNF-α receptor  knock-out  mice  were  not 
eliminated although production of IL-4 and IL-13 were altered. Thus in endemic 
areas, vaccines that induce a Th2 response protect against the parasite.68,108-111
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Clinical features
The cerebral  manifestations of  cysticercosis  are diverse,  related to  the 
encystment  and  subsequent  calcification  of  the  larvae  in  the  cerebral 
parenchyma,  subarachnoid  space  and  ventricles.  Most  often  the  neurologic 
disease  presents  with  seizures,  although  many  patients  are  entirely 
asymptomatic, the cysts being discovered radiologically. It is only when the cyst 
degenerates  over  many  months  or  years  after  the  initial  infestation,  that  an 
inflammatory and granulomatous reaction is elicited and focal symptoms arise.31 
Symptoms vary according to the location of the cyst, the parenchymal and 
extraparenchymal  neurocysticercosis.  The  usual  presentation  of  parenchymal 
neurocysticercosis  is  with  seizures,  which  can be controlled with  antiepileptic 
drug  therapy.  Occasionally,  the  cysts  may grow and  produce a  mass effect. 
Extraparenchymal infection may cause hydrocephalus by mechanical obstruction 
of the ventricles or the basal cisterns, either by the cysts themselves or by an 
inflammatory  reaction  (ependymitis  and/or  arachnoiditis).  The  so-called 
racemose variety occurs in the ventricles or basal cisterns and is characterized 
by abnormal  growth  of  cystic  membranes with  degeneration  of  the parasite’s 
head  (scolex).112  These  cases  follow  a  progressive  course,  and  even  after 
ventricular  shunting,  the  membranes  or  inflammatory  cells  and  proteins 
frequently block the shunt.113
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Diagnosis of Neurocysticercosis
The diagnosis of NCC is based on clinical findings, neuro-imaging (CT/MRI) and 
serological tests. Epidemiology can be helpful. The diagnosis can however be 
difficult as seizures, headache, focal deficits are common to several neurological 
disorders,  neuro-images  of  cysticerci  are  not  pathognomonic  and  serological 
tests are not always sensitive for  infections with  calcified or a low number of 
cysts.114-124
Neuro-imaging
The  natural  history  of  parenchymal  cysticercosis  has  been  studied  by 
imaging  studies  using  Computed  Tomography  (CT)125,126  and  Magnetic 
Resonance Imaging (MRI).127(Fig.5,6)   Viable cysts are 10 to 20 mm in diameter, 
thin-walled sacks filled with clear cyst fluid. On imaging studies, the wall is not 
visible and the fluid is isodense with the cerebrospinal fluid. There is little or no 
evidence of perilesional  inflammation,  and they do not  enhance with  contrast 
media  on  neuroimaging.  As  the  parasite  loses the  ability  to  control  the  host 
immune response, an inflammatory process begins. Initially, the cysts show slight 
pericystic  contrast  enhancement.  Later  they  become  markedly  inflamed  and 
edematous and appear as ring-like or nodular areas of enhancement after the 
injection of contrast. This phase has been called “granulomatous cysticercosis, 
“cysticerci  in  encephalitic  phase,”  or  “enhancing  lesions.”  Finally,  the  cyst  is 
processed by the cellular response, and its remnants either are not detectable by 
imaging or become calcified lesions. “Giant” cysts, measuring more than 50 mm 
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in  diameter,  are  occasionally  found,  located  primarily  in  the  sylvian  fissure. 
Cysticercotic encephalitis is a rare form of the disease in which patients have 
numerous  inflamed  cysticerci,  leading  to  severe  diffuse  cerebral  edema. 
Extraparenchymal  neurocysticercosis  includes  cysticerci  in  the  ventricles  and 
basal cisterns (racemose cysticercosis). Since the cyst membrane is thin and the 
fluid  is  isodense  with  the  cerebrospinal  fluid,  uninflamed  extraparenchymal 
cysticerci  are  usually  not  visible  on  CT and  may only  reveal  subtle,  indirect 
findings  on  MRI.  Scans  may  reveal  hydrocephalus  without  noticeable  cysts, 
ependymitis, distorted basal cisterns, or basal meningitis.113 
           
Fig. 5: Multiple NCC Fig.6: Solitary NCC
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Serodiagnosis
Serological  tests  confirms  diagnosis  and  are  especially  useful  in 
differential  diagnosis  of  NCC  from  tuberculomas,  pyogenic  brain  abscess, 
mycotic granulomas,  brain tumors and other conditions in which neuro-images 
can be similar. Serological tests are also valuable when radiological imaging is 
not available or too expensive.  They have been important in epidemiology of 
cysticercosis. Cysticercosis demographics in most populations have largely been 
determined from serological data.114,115,128-134
There are numerous sero-immunological tests for T solium cysticercosis in 
several  assay  formats.  There  are  assays  to  detect  T  solium antigens  and 
cysticercus antibodies in saliva,  blood, CSF and urine by ELISA and immune 
blots.  Assays  of  blood,  urine,  and  saliva  determine  both  systemic  and  CNS 
cysticercosis.  Tests  for  cysticercus  antigens indicate an active  infection while 
those for antibodies determine both past and current infections, as cysticercus 
antibodies  persist  for  a  long  period  of  time  (even  for  two  years)  after  an 
infection.135-141 
Serological tests for  T solium cysticercosis are possible because of the 
immunogenic character of the parasite proteins. In  T solium neurocysticercosis 
the immune response is determined by the number, stage of development and 
location  of  cysts  in  the  brain  and  influenced  by  the  immune  suppressive 
properties  of  the  antigens.  Cysticercus  antibody  levels  are  stated  to  be 
decreased in infection of low cyst numbers and when cysts are calcified.142-144
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Serological testing for cysticercosis began almost 100 years ago when in 
1909 Weinberg demonstrated, by fixation, the presence of cysticercus antibodies 
in sera of pigs infected with “Cysticercus cellulosae”. The assay quickly moved 
into human testing. In 1911 Arthur Moses in Brazil using an aqueous extract of 
cysticercus cellulosae established for the first time cysticercus antibodies in the 
sera of 3 patients with cutaneous cysticercosis and in the CSF of one patient with 
encephalitic cysticercosis.145,146
Early serological tests mostly used crude antigen extracts for cysticercus 
antibody detection and consequently were associated with  high rates of  false 
positive and negative reactions.147-149  Identification of specific T solium antigens, 
purification  of  antigens,  use  of  recombinant  DNA  technology  and  hybridoma 
science have in the last two decades greatly improved these serological tests. 
Most assays in current use are sensitive and specific for  T solium cysticercosis 
and  their  limitations  of  cross  reactivity  and  false  negative  reactions  well 
described.150-160
A large  number  of  the  immune assays  use  T solium glycoproteins  as 
antigens  given  their  immunogenic  preponderance  in  the  parasite.  Antigenic 
glycoproteins useful  for the detection of serum antibodies are mostly of small 
molecular weight (<50kDa). Cyst antigens of 13, 14, 18, 24, 38 and 50kDa were 
identified to be infection specific for T solium cysticercosis. Purification of these 
glycoproteins  has  been  by  classical  methods  of  lentil  lectin  affinity 
chromatography  and  pH  dependence.161-163   CSF  cysticercus  serology  has 
benefited from use of a very small protein of 10kDa.164
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The complex glycosylation of T solium antigenic glycoproteins is essential 
for  optimal  serological  performance. Recombinant  T solium proteins have not 
performed as well  as the native antigens in serological  tests.  The inability  of 
recombinant systems to synthesize glycosyl units to the complexity required is 
stated to be the major reason for the lower performance of these systems. Work 
on high quality recombinant  T solium antigens carries on unabated because of 
the immense advantage of  using recombinant  proteins over  difficult  to  obtain 
native  antigens,  in  serological  tests  required  world  wide  for  an  infectious 
disease.150,151,156,165
 Infectious  disease is  best  diagnosed by the presence of  the infecting 
organism. Monoclonal antibodies produced to excretory and secretory antigens 
of the parasite, which detect the antigens in circulation, provide this diagnostic 
criterion  for  T solium cysticercosis.  It  is  natural  that  the seroprevalence of  T 
solium cysticercosis,  among  patients  and  in  populations,  determined  by  the 
antigen assays are lower than levels obtained from determining prevalence of 
cysticercus antibodies.51,117,166-170
Serological assays for cysticercosis in current use are reliable for multi-
cyst infections. In the natural, variable history of T solium cysticercosis, multi-cyst 
infections  ensure  sufficient  antigens  for  immune  stimulation.  The  tests  are 
inadequate for infections with low numbers of cysts especially those categorized 
as solitary cyst infections of the CNS. In large parts of the world this does not 
matter as T solium infections are predominantly multi-cystic. In countries where T 
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solium infections of the CNS are common but of low cyst number, as in India, the 
assays must be improved.5,7,8,10,114,115,124 
Diagnostic criteria
Diagnostic criteria for NCC currently suggested are given in Table 1, and 
classified as absolute, major, minor and epidemiological criteria. The criteria 
among these four groups required for a definite or probable diagnosis of NCC are 
given in Table 2. CT criteria for solitary cysticercus granuloma are well 
established and have a sensitivity and specificity of 99% (Table 3).5,7,8,10,171
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Table 1: Diagnostic criteria for neurocysticercosis171
Categories of 
criteria Criteria
Absolute
1. Histologic demonstration of the parasite from biopsy of a brain or spinal 
cord lesion
2. Cystic lesions showing the scloex on CT or MRI
3. Direct visualization of subretinal parasites by fundoscopic examination
Major
1. Lesions highly suggestive of neurocysticercosis on neuroimaging studies*
2. Positive serum EITB† for the detection of anticysticercal antibodies
3. Resolution of intracranial cystic lesions after therapy with albendazole or 
praziquantel
4. Spontaneous resolution of small single enhancing lesions‡
Minor
1. Lesions compatible with neurocysticercosis on neuroimaging studies§
2. Clinical manifestations suggestive of neurocysticercosis# 
3. Positive CSF ELISA for detection of anticysticercal antibodies or 
cysticercal antigens
4. Cysticercosis outside the CNS¶
Epidemiologic
1. Evidence of a household contact with Taenia solium infection
2. Individuals coming from or living in an area where cysticercosis is 
endemic
3. History of frequent travel to disease endemic areas
*     CT  or  MRI  showing  cystic  lesions  without  scolex,  enhancing  lesions  or  typical 
parenchymal brain calcifications
†    Enzyme-linked immunoelectro  transfer blot  assay using purified extracts of  taenia 
solium antigens,  as  developed  by  the  Centers  for  Disease  Control  and  Prevention 
(Atlanta, GA)
‡    Solitary  ring-enhancing lesions measuring less than 20mm in diameter  in patients 
presenting with seizures, a normal neurological examination and no evidence of an active 
systemic disease
§    CT or MRI showing hydrocephalus or abnormal enhancement of the leptomeninges, 
and myelograms showing multiple filling defects in the column of contrast medium
#    Seizures, focal neurologic signs, intracranial hypertension and dementia
¶    Histologically confirmed subcutaneous or muscular Cysticercosis,  plain X-ray films 
showing “cigar-shaped” soft tissue calcifications or direct visualization of cysticerci in the 
anterior chamber of the eye
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Table 2: Degrees of certainty for the diagnosis of neurocysticercosis171
Diagnostic 
certainty
Criteria
Definitive
1. Presence of one absolute criterion
2. Presence of two major plus one minor and one epidemiologic 
criterion
Probable
1. Presence of one major plus two minor criterion
2. Presence of one major plus one minor and one epidemiologic 
criterion
3. Presence of three minor plus one epidemiologic criterion
The presence of two different lesions highly suggestive of neurocysticercosis on neuroimaging 
studies should be considered as two major diagnostic criteria. Positive results in two separate 
types of antibody detection tests should be interpreted only on the basis of the test falling in the 
highest category of diagnostic criteria
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Table 3: Clinical and CT criteria for the diagnosis of an SCG9
All criteria must be satisfied to make a diagnosis of SCG
Clinical features − patient should present with seizures
− there  should  be  no  features  of  persistent  raised 
intracranial pressure
− there  should  be  no  evidence  of  a  progressive 
neurological deficit, and
− there should be no evidence of a systemic disease 
such  as  a  primary  malignancy,   pulmonary  or 
systemic  tuberculosis  and  focus  of  pyogenic 
infection.
CT features − the lesion should be solitary
− the lesion should enhance with contrast injection
− the  lesion  should  measure  less  than  20mm  in 
maximal dimension, and
− edema may or may not be present around the lesion 
but if present should not be severe enough to cause 
a shift of the midline structures.
Proposed 
additional 
criteria
1) Epidemiological- history of residence in or travel to 
regions of the world endemic for cysticercosis; 
2) Immunological-  a  positive  enzyme  linked 
immunotransfer blot assay for cysticercus antibodies 
in serum or CSF.
SCG – Solitary Cysticercal Granuloma CSF – Cerebro Spinal Fluid 
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MATERIALS AND METHODS
Study design
Peripheral blood mononuclear cells from neurocysticercosis patients and 
healthy  controls  were  isolated  and  stimulated  in  culture  for  24  hours  with  T 
solium infection specific glycoproteins of 13, 14, 18, 24, 38 and 50kDa, their N-
glycan  and  peptide  components  separately.  The  culture  supernatants  were 
assayed for IL-12 as a marker for Th1 inflammatory response, IL-4 as a marker 
for Th2 anti-inflammatory response and nitric oxide. The profiles were compared 
between  healthy  controls  and  patients,  further  between  solitary  and  multiple 
cysticercosis patients to determine the immune response stimulated by T solium 
infection.
Approval
The study was approved by Institutional Review Board and Human Ethics 
Committee of our institution. 
Subjects
Fourteen patients with NCC, (8 MNCC; 6 SCG) and 6 healthy controls 
were studied.
All patients were on their first visit to the Neurology service of the hospital. 
Detailed  history  and  neurological  examination  was  performed on  all  patients. 
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Serological  test  for  cysticercal  antibodies  and  contrast  enhanced  CT/MRI 
examination was performed on all patients.
Inclusion criteria
Patients  with  history  of  recent  onset  seizures  (<  6  months),  focal  or 
generalized, raised intracranial tension or both who fulfilled the diagnostic criteria 
for SCG or MNCC mentioned earlier were included in the study.  
Exclusion criteria
Known cases of epilepsy and those who had received cysticidal drugs or 
steroids were excluded from the study. 
Controls
Asymptomatic, healthy volunteers among laboratory staff, matched for age 
to patients were included as controls; all of them were negative on the EITB for 
cysticercus antibodies.
Experimental methods
Enzyme-linked Immunoelectro Transfer Blot (EITB):
Cysticercal  antibodies  were  assayed  in  serum by the  EITB method.  A 
sample was considered positive for cysticercal antibodies on the appearance of 
immune bands  to  one  or  more  of  the  seven  T solium infection  specific  cyst 
glycoproteins of molecular weight 13kDa - 50kDa.114
44
Peripheral blood mononuclear cell cultures
Twelve  ml  venous  blood  was  drawn  from  all  subjects  with  informed 
consent. Peripheral blood mononuclear cells (PBMCs) were isolated from blood. 
One million PBMCs in RPMI 1640 / 10% newborn calf serum were seeded in 24 
well culture plates and cells in each well, stimulated with one infection specific T 
solium glycoprotein antigen, its N-glycan and peptide components. Cells were 
cultured  for  24  hours  at  37ºC  in  5%  CO2  /  95%  air  (humidified).  Culture 
supernatants were assayed for IL-12, IL-4 and nitric oxide (NO).
Cells  from  each  subject  were  therefore  separately  stimulated  with  21 
components of each of the seven infection specific antigens.  
Cytokine and NO assays in PBMC culture supernatants
PBMC culture supernatants were assayed for IL-4 and IL-12 by ELISA as 
described by the  manufacturer.  Briefly,  microtitre  plates  pre-coated with  anti-
IL-12 / IL-4 polyclonal antibodies were incubated with culture supernatants and 
IL-4 or IL-12 detected with biotin conjugated monoclonal anti-IL-12 / IL-4 antibody 
followed by streptavidin-peroxidase.
Nitrate,  the  stable  end  product  of  nitric  oxide,  was  assayed  in  culture 
supernatants  by  the  Greiss  reaction  after  reduction  with  copper-cadmium  to 
nitrite.172
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Statistical analysis
Data was analyzed for differences between controls and patients by the 
nonparametric Mann Whitney U-Test in consideration of small sample size. Tests 
were considered significant at p < 0.05. Statistical analysis was carried out using 
SPSS 13.0 software.
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RESULTS
Patients: Fourteen patients were included in the study, 6 SCG and 8 MNCC. 
Thirteen  of  the  14  presented  with  recent  onset  seizures  (<6  months).  Two 
patients  had  intracranial  hypertension,  one  with  seizures  and  one  without 
seizures; both had MNCC, numerous cysts (>100) in the brain (Table 4).
On brain imaging all patients had ring enhancing lesions of less than 2cm 
in size; stages of the cysts varied from vesicular, colloid to granular-nodular and 
all of them were parenchymal cysts. Serology was positive in all MNCC patients 
and in only 2 of the SCG patients (Table 4).
CSF  analysis  (Table  5)  was  done  in  12  of  the  14  patients.  Cytology 
showed predominant lymphocytes in all patients. 3 patients had pleocytosis (80, 
40 and 20 cells respectively), all three had elevated protein (111, 92 and 63 mg% 
respectively).  
47
Table 4: Patient characteristics
*↑ ICT in 1 patient with seizure and 1 without seizure; # Serology not done in 1 SCG patient
Table 5: CSF characteristics
NCC Type No Cells/c.mm Protein (mg%)
<5 >5 <60 >60
Sugar (mg%)
Patients No
Mean 
Age 
(years)
Sex
M:F
Seizure
GTCS Focal
↑ ICT*
Imaging Serology #
Single cyst <5 cysts >100cysts Positive Negative
SCG 6 29 4:2 6 - - 6 2 (33%) 3 (50%)
MNCC 8 31 7:1 4 3 2 (25%) - 5 3 8 (100%) -
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SCG 4† 2 2 4 - N
MNCC 8 5 3* 4 4 N
†CSF not done for 2 SCG patients, *all 3 with pleocytosis had ↑protein
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PBMC response to T solium antigens: IL-12 (Table 6)
IL-12 was secreted by PBMCs from both controls and NCC patients in 
response  to  challenge  by  T  solium antigens.  N-glycans  were  significantly 
stronger stimulants of the response than their corresponding glycoproteins. No 
significant  response  was  observed  in  cells  challenged  with  peptides  of  the 
glycoproteins.
Controls showed a significantly higher IL-12 response compared to NCC 
patients in response to challenge by pure T solium infection specific antigens. 
IL-12 response was significantly higher in patients with MNCC compared 
to those with SCG, when stimulated with N-glycans and no significant difference 
was observed with glycoprotein antigen. 
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Table 6: Interleukin-12 levels in culture supernatants of PBMCs stimulated with T solium antigens
T  solium 
glycoprotein
PBMC culture supernatant – IL-12 pgm/ ml (Mean ± SEM)
Control (n=6) NCC (n=14) MNCC (n=8) SCG (n=6)
Glycoprotein Glycan Glycoprotein Glycan Glycoprotein Glycan Glycoprotein Glycan
LLGP 6.68 ± 3.15 8.81 ± 4.23 18.51±4.12 36.43±8.18# 19.2 ± 6.38 39.3± 15.0 17.5 ± 6.60 32.5 ± 5.93#
50kDa 17.8 ± 11.4 16.9 ± 5.82 1.40±0.63 3.33±0.88# 1.15 ± 0.73 4.60 ± 1.46#† 1.73 ± 1.32 1.64 ± 0.55#
38 kDa 13.9 ± 7.14 12.4 ± 2.89 0.30±0.15 1.36±0.46# 0.14 ± 0.14 1.37 ± 0.78# 0.50 ± 0.31 1.34 ± 0.56#
24 kDa 37.7 ± 21.5 60.7 ± 26.8 5.95±1.83* 13.83±2.96# 5.64 ± 2.89* 15.8 ± 4.69 6.35 ± 2.81 9.47 ± 1.50#
18 kDa 7.07 ± 1.95 14.1 ± 4.13 0.54±0.22* 2.28±0.70# 0.3 ± 0.22* 3.04 ± 1.25# 0.86 ± 0.47* 1.25 ± 0.17#
14 kDa 15.3 ± 6.20 23.8 ± 13.6 3.12±1.00* 10.24±1.89 2.93 ± 1.53* 13.3 ± 2.60† 3.37 ± 1.61* 6.12 ± 2.36
13 kDa 20.1 ± 6.15 32.4 ± 12.8 3.27±1.02* 11.14±2.23# 3.15 ± 1.69* 13.4 ± 2.97 3.43 ± 1.38* 8.00 ± 3.85#
* p<0.05 Compared to controls (Glycoprotein as antigen); # p<0.05 Compared to controls (Glycan as antigen)
†p<0.05 MNCC compared to SCG (Glycan as antigen)
51
PBMC response to T solium antigens: IL-4 (Table 7)
IL-4 was secreted by PBMCs from NCC patients but not from controls in 
response  to  challenge  by  T  solium antigens.  N-glycans  were  significantly 
stronger stimulants of the response than their corresponding glycoproteins. No 
response was observed in cells challenged with peptides of the glycoproteins. 
The IL-4 response was greatest in NCC patients when cells were stimulated with 
Lentil Lectin Glyco Protein (LLGP).
The  IL-4  response  was  significantly  greater  from  SCG  than  MNCC 
patients against lower molecular weight glycoproteins and the N-glycans (18, 14 
and 13kDa components). 
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Table 7: Interleukin-4 levels in culture supernatants of PBMCs stimulated with T solium antigens
T  solium 
glycoprotein
PBMC culture supernatant – IL-4 pgm/ ml (Mean ± SEM)
Control (n=3) NCC (n=14) MNCC (n=8) SCG (n=6)
Glycoprotein Glycan Glycoprotein Glycan Glycoprotein Glycan Glycoprotein Glycan
LLGP 0.1 ± 0.0 0.03± 0.03 80.8±9.30* 76.7±10.5‡ 75.4 ± 17.2* 85.1± 17.7‡ 88.0±5.31* 85.4±5.62‡
50kDa 0 0.13± 0.16 3.45±1.09* 9.56±6.17 2.36 ± 0.97 2.71 ± 0.84 4.9±2.44* 19.1±15.3
38 kDa 0 0 4.44±1.36* 7.65±3.26‡ 3.02 ± 0.96* 10.6 ± 6.94 6.31±3.18* 13.8±7.71‡
24 kDa 0 0.73 ± 0.89 17.5±5.86* 35.5±16.7 7.35 ± 2.24* 7.99± 2.30 31.0±12.7* 73.0±37.8
18 kDa 0.27 ± 0.16 0.42 ± 0.31 8.45±3.53* 11.5±3.92 3.31 ± 1.34 9.92 ± 7.02 15.3±8.221*# 22.5±7.56‡†
14 kDa 0.42 ± 0.01 1.02 ± 1.02 14.3±6.0 22.2±8.30 5.90± 2.55 15.3 ± 9.59 25.7±13.9*# 43.9±17.0‡†
13 kDa 1.48± 0.44 2.23 ± 0.03 17.1±6.41 26.9±10.3 5.71± 2.68 28.7± 18.0 32.4±13.6*# 55.2±20.7‡†
* p<0.05 Compared to controls (Glycoprotein as antigen); # p<0.05 MNCC compared to SCG (Glycoprotein as antigen)
‡ p<0.05 Compared to controls (Glycan as antigen); † p<0.05 MNCC compared to SCG (Glycan as antigen)
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PBMC Th1 / Th2 response in NCC
The relative Th1 and Th2 profiles of healthy controls and NCC patients to 
challenge by T solium infection specific antigens was determined from the total 
IL-12 and IL-4 response to the 50, 38, 24, 18, 14 and 13kDa antigens (i.e., to all 
infecting T solium glycoproteins)
The PBMC response to all infecting  T solium glycoproteins shifted from 
pro-inflammation Th1 (98%) in healthy controls to anti-inflammation Th2 (82%) in 
all  NCC, 88% in SCG and 67% in MNCC.(Fig.7)  The response with glycans 
shifted from Th1 to Th2 from 97% in controls to 79% in all NCC, 89% in SCG and 
67% in MNCC. (Fig.8)
Fig.7: Th1/Th2 response by PBMCs to T solium glycoproteins of 13-50 kDa
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NCC
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Fig.8: Th1/Th2 response by PBMCs to T solium glycans of 13-50 kDa
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In controls the Th1 response was 51.6 fold higher than the Th2 response 
with glycoproteins and 35.4 fold higher with N-glycans.
In all NCC patients the Th2 response was 4.5 fold higher than the Th1 
response in PBMCs challenged with T solium glycoproteins. This Th2 response 
56
was 7.1 fold higher than the Th1 response in patients with SCG while only 2.1 
fold higher in patients with MNCC.
In all NCC patients the Th2 response was 2.7 fold higher than the Th1 
response in PBMCs challenged with T solium N-glycans. This Th2 response was 
7.8 fold higher than the Th1 response in patients with SCG while only 1.5 fold 
higher in patients with MNCC.
Nitric oxide (Table 8)
NCC patients produced significantly higher nitrate than the controls, but 
there was no difference between MNCC and SCG patients. The N-glycans were 
stronger  stimulants  of  nitric  oxide  production  than  the  corresponding 
glycoproteins. The pure infection specific antigens were stronger stimulants of 
nitric oxide production than the LLGPs. No nitric oxide response was observed in 
cells challenged with the peptides of the glycoproteins.
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Table 8: Nitrate levels in culture supernatants of peripheral blood mononuclear cells stimulated with T solium 
antigens. (glycoprotein component)
T  solium glycoprotein
PBMC culture supernatant – nmoles nitrate / ml (Mean ± SEM)
Control (n=6) NCC (n=14) MNCC (n=8) SCG (n=6)
LLGP 0.21 ± 0.05 2.29 ± 0.73* 1.55 ± 0.53 3.29 ± 1.64*
50kDa 14.35 ± 3.56 92.84 ± 29.47* 76.15 ± 19.98* 115.1 ± 69.88*
38 kDa 9.80 ± 3.84 47.17 ± 11.91* 41.73 ± 13.57 54.43 ± 24.00*
24 kDa 4.99 ± 0.53 98.18 ± 28.89* 82.99 ± 20.38 * 118.43 ± 68.23
18 kDa 7.18 ± 1.80 22.11 ± 4.21* 24.53 ± 6.73 18.9 ± 5.19*
14 kDa 11.83 ± 3.20 56.92 ± 14.99 64.40 ± 24.47 46.93 ± 17.44
13 kDa 13.45 ± 4.89 95.54 ± 25.65* 129.02 ± 42.08* 50.89 ± 11.86*
* p<0.05 when compared to Controls
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DISCUSSION
Development of neurocysticercosis following exposure may be influenced 
by  the  endemicity,  number  of  exposures,  egg-load  and  the  presence  of  co-
infections.  The immune response of  the host,  both humoral  and cellular  also 
plays  a  major  role  in  determining  the  outcome  namely,  clearance  versus 
establishment of infection.
It  has been shown in animals that immunity against helminth infections 
requires the induction of a Th1 (pro-inflammatory)  response, while infection is 
established by induction of a Th2 (anti-inflammatory) response by the host.91,173,174 
Taenia infection in mice indicates a Th1 response protects the animals against 
the  parasite,  while  a  Th2  response  is  necessary  to  establish  infection.175 T 
crassiceps infected BALB/c mice developed an initial brief Th1 like response that 
is replaced by a strong Th2 response associated with parasitemia.87  Nitric oxide 
and macrophage activation also contribute to resistance against taenia infections 
in mice.88
The cellular response has not been so clearly defined in human  taenia 
infections especially neurocysticercosis,  but  may impact  on disease profile.  A 
predominantly  Th1  pro-inflammatory  environment  that  mostly  clears  infection 
may  result  in  solitary  cyst  disease,  while  infections  that  are  not  cleared 
completely give rise to MNCC. This process would also be dependent on innate 
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immunity  that  is  determined  not  only  by  the  infecting  organism  but  also 
modulated  by  co-infections  and  bystander  antigens  which  differ  between 
populations.
To  explore  the  influence  of  host  immunity  and  cyst  number  in  NCC 
patients  in  Indian  population,  the  response  of  PBMCs  to  infecting  T  solium 
glycoproteins  was  compared between healthy young adults  and patients  with 
multi-cyst and solitary cyst infections. The immune response to N-glycans of the 
infecting  T  solium glycoproteins  was  also  studied  in  view  of  their  critical 
importance for cysticercus antibody recognition. IL 12 was measured as a marker 
of the Th1 response and IL4 of Th2 response. The possible role of nitric oxide in 
protecting the host against infection and thus contributing to magnitude of cyst 
load was also studied.
Symptomatic  NCC  is  associated  with  depressed  cellular  but  active 
humoral  responses.  This  has  been  noted  in  patients  from Mexico.104  In  the 
present study all our patients presented soon after seizures and were considered 
to be symptomatic. They exhibited both active cellular and humoral immunity. In 
this study all controls with no cysticercosis (i.e., EITB negative) elicited a Th1 
response and all  patients,  both SCG and MNCC, elicited a predominant  Th2 
response.  This would support the idea of a pro-inflammatory cytokine milieu, 
produced  in  the  early  interaction  of  parasite  with  host  that  protects  against 
parasite  invasion  and  eliminates  infection,  while  an  anti-inflammatory 
environment  allows  for  the  survival  of  parasite  and  establishment  of  cyst 
formation.  Our  NCC  patients,  both  SCG  and  MNCC  had  low  levels  of  Th1 
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response (suppressed Th1 response) to establish infection. This is in contrast to 
an earlier study of cellular immunity in Indian patients with neurocysticercosis,176 
which  showed a predominant  Th1 response of  PBMCs stimulated with  crude 
soluble extract antigen and antigen B. The reason for this difference is not clear, 
but may be due to the nature of the different stimulating cyst antigens. 
It  is also possible that the relatively lower anti-inflammatory,  but higher 
pro-inflammatory response noted with MNCC compared to SCG signify ongoing 
elimination reactions that the host does not perceive as necessary in a single 
cyst disease. 
The results of the study suggest that non-infected host may be protected 
against  the establishment  of  infection by robust  pro-inflammatory reactions to 
infectious  challenge.  The  establishment  of  infection  is  accompanied  by 
suppression  of  pro-inflammation  and  supported  by  an  anti-inflammatory 
response.  Thus immunity in the present study group with NCC may transit from 
early  protective,  pro-inflammatory  Th1  reactions  to  anti-inflammatory  Th2 
responses that permit parasite to survive in the host.
Cytokines associated with T solium cystic lesions in the brain are found to 
be largely pro-inflammatory Th1. This has also been seen in murine cysticercus 
granulomas.90,97,174  It  is  not  known  if  the  compartmentalized  CNS  cytokine 
profiles in patients with NCC differ from those in periphery and whether CNS 
cytokines  differ  between patients  with  multiple  versus solitary  cysts  and their 
impact on cyst load.
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Helminth  infections  are  considered  to  down  regulate  cellular  immune 
response. This was not seen in the humoral response of the patients as most of 
them possessed antibodies to infection specific T solium glycoproteins. The Th2 
response in infection, that permits parasite survival,  may be accomplished by 
down  regulation  of  the  inflammatory  response  by  immune  suppressive  cyst 
antigens. A similar understanding emerges from the CNS in murine cysticercosis 
where granulomas with dying cysts secrete Th1 cytokines that lead to clearing of 
parasite. As this occurs the response is modulated to Th2 expression, implicating 
down regulation of the granulomatous response.174 
In animals protection against taenia infections is also provided by elevated 
NO, implying macrophages are necessary for  protection against cysticercosis. 
Mice treated with nitric oxide synthase inhibitors are susceptible to T crassiceps 
infection and increased parasite loads.88,177  In this study increased nitric oxide 
levels in NCC patients in response to taenia antigens may indicate NO toxicity to 
the  parasite  and  implicate  NO  and  macrophage  in  protection  against 
cysticercosis.
In the present study even though we found predominant Th1 response in 
controls, with  no significant Th2 response, there was no significant difference 
between the SCG and MNCC groups, both eliciting a dominant Th2 response. It 
is possible that the reacting cells resulting in cytokine secretion  in the control 
group may be the infection naïve cells, thus representing the early phase in the 
infection,  showing  Th1  response  at  this  particular  point  of  time  when  the 
cytokines were examined. Had the cytokine examination been conducted over a 
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period of time with serial samples, it may have been possible to demonstrate the 
shift of the immune response from early protective Th1 to late permissive Th2 
response.  Similarly  in  the  NCC  group,  both  SCG  and  MNCC,  the  cells  are 
probably mixed population with infection naïve and pre-exposed memory cells, 
leading to establishment of early shift from Th1 to Th2 response, (memory cells 
lead to more rapid and often more vigorous immune response) thus resulting in 
dominant Th2 response in both SCG as well as MNCC observed in our study.
In this complex immune response, a temporal profile of a wider repertoire 
of  Th1  and  Th2  cytokines  of  both  naïve  cells  and  memory  cells  in 
neurocysticercosis may help in elucidating the transition of Th1 to Th2 response 
in taenia infection.
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CONCLUSIONS
1. Non-infected individuals mounted a strong pro-inflammatory response to 
Taenia solium infection specific cyst antigens.
2. Neurocysticercosis  elicited  predominant  anti-inflammatory  response  to 
Taenia solium infection specific cyst antigens, which did not differ between 
solitary and multiple cyst infections.
3. Immunity  in  the  present  study  group with  NCC may transit  from early 
protective,  pro-inflammatory  Th1  reactions  to  anti-inflammatory  Th2 
responses that permit parasite to survive in the host.
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APPENDIX 
PROFORMA FOR COLLECTION OF DATA
Name of the patient: Age:
Sex: MALE/FEMALE Occupation:
Hospital No: Date:
Presenting complaints:
1) Seizures: Focal/GTCS/Secondary generalized
2) Raised ICT: Headache/ vomiting/ diplopia/ blurring of vision
3) Focal deficit: Cranial Nerves / Motor / Sensory / Cerebellar
Past history:
H/o seizures/epilepsy
Drug history:
H/o steroid/cysticidal drug intake
Examination findings:
General examination:
Subcutaneous nodules /  Nodules in the tongue
Nervous system:
Higher mental function
Cranial nerves
89
Motor system
Sensory system
Cerebellum
Skull and spine
Investigations:
Complete Blood Count, ESR
Chest X ray
Serum creatinine, glucose
Serum cysticercal antibody (EITB)
Cerebrospinal fluid
-Cells:TC,DC,RBC
-Protein,glucose
-AFB smear/culture
-Routine smear/culture
-Fungal smear/culture
CT/MRI Brain with contrast
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MASTER CHART
Pts Sex Ageyears
Clinical data
Seizures
Focal GTCS
Raised ICT
Past history EITB
CSF Imaging
cells protein glucose No. of cysts Stage of cysts
1 M 41 - Yes Raised ICT Nil Positive 80(L94) 111 78 Numerous V/G
2 M 21 - Yes Nil Nil Positive 3(L) 34 60 4 G/N
3 M 14 Lt focal - Nil Nil Positive 2(L) 20 46 2 C
4 M 64 Rt focal - Nil Nil Positive 5(L) 63 61 2 C
5 M 16 Rt focal - Nil Nil Positive 1(L) 28 63/77 2 C
6 M 38 - Yes Nil Nil Positive 20(L98) 63 57 Numerous G/N
7 F 31 - Yes Nil Nil Positive 3(L) 23 72 3 G
8 M 26 - Yes Papilledema Nil Positive 40(L98) 92 57 Numerous All
9 F 74 - Yes Nil GTCS-1 yr back Not done 1(L) 56 82/248 1 C/G
10 M 21 - Yes Nil Nil NEGATIVE Not done 1 C/G
11 M 23 - Yes Nil Nil Positive 2(L) 27 74 1 C/G
12 F 18 - Yes Nil Nil Positive 22 (L99) 47 43/82 1 C/G
13 M 19 - Yes Nil Delayed development NEGATIVE 15 (L99) 37 78/130 1 C/G
14 M 18 - Yes Nil Nil NEGATIVE Not done 1 C/G
ICT – Intra Cranial Tension GTCS – Generalized Tonic Clonic Seizures EITB – Enzyme linked Immuno Transfer Blot
CSF – Cerebro Spinal Fluid V – Vesicular C – Colloid G – Granular N – Nodular  
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Data for IL12 secretion in PBMC -  (IL12 pg/ml /ngm stimulant / million cells) MNCC (8)
GPS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
1 5.4 1.1 1.6 0 0 0 40 8.1
2 0 0 0 0 0 0 3.96 0
3 0 0.07 0 0 0.06 0 0.16 0.13
4 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 18.8 0
6 0.2 0 11.1 0 8 8.5 42 27.8
7 2.64 0 18.67 0.8 8.8 10.5 20.8 41.41
8 1 0 13.8 1.6 6.6 6.2 28 29.2
Mean 1.155 0.146 5.646 0.3 2.9325 3.15 19.215 106.64 153.72
SD 1.945 0.386 7.650 0.595 4.074 4.496 16.886
SEM 0.735 0.145 2.891 0.224 1.539 1.699 6.382
GLYCANS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
1 4 5.8 42 10.8 21.3 28 100 111.9
2 13.7 0.69 2.05 4.16 12.4 5.42 3.8 38.42
3 3.28 1.16 11.4 1.68 3.53 5.25 2.08 26.3
4 5.2 0.24 13.8 2.7 5.3 15.7 6.4 42.94
5 4.2 3.1 6.6 1 15.1 15.7 18 45.7
6 2.6 0 11.1 0.6 12.2 7.1 39 33.6
7 2.64 0 24.4 1.79 23.5 19.32 95.5 71.65
8 1.2 0 15.5 1.6 13.3 11.4 50 43
Mean 4.602 1.373 15.856 3.041 13.328 13.486 39.347 413.51 314.78
SD 3.869 2.071 12.418 3.320 6.894 7.860 39.891
SEM 1.462 0.782 4.693 1.255 2.605 2.971 15.077
PEPTIDES Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
1 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0
3 0.016 0.006 0.009 0 0.004 0.004 0
4 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0
6 NOT DONE
7 NOT DONE
8 NOT DONE
Mean 0.003 0.001 0.001 0 0.0008 0.0008 0
SD 0.007 0.002 0.004 0 0.0017 0.0017 0
SEM 0.003 0.001 0.002 0 0.0008 0.0008 0
Data for IL12 secretion in PBMC (IL12 pg/ml /ngm stimulant / million cells) SCG (6)
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GPS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
9 0 1.45 5.4 0.64 2.04 1.94 8.4 11.47
10 0 1.34 2.55 0.24 0 1.88 1 6.01
11 7.6 0.25 2.5 1.5 2.53 2.57 9 16.95
12 0 0 0 0 0 0 17 0
13 1 0 11.1 0.1 8.2 8.5 40 28.9
14 1.8 0 16.6 2.7 7.5 5.7 30 34.3
Mean 1.733 0.506 6.358 0.863 3.378 3.431 17.566 97.63 105.4
SD 2.965 0.695 6.294 1.053 3.621 3.097 14.765
SEM 1.326 0.311 2.815 0.470 1.619 1.385 6.603
GLYCANS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
9 0 2.72 7.55 1.57 3.2 3.82 25.8 18.86
10 2.64 2.36 7.33 1.46 2.93 4 25.8 20.72
11 2.64 2.4 7.2 1.4 2.86 3.68 25.8 20.18
12 2.58 0.43 7.16 1.41 2.93 4.05 25.8 18.56
13 1.8 0.18 13.8 0.5 15.7 25.4 59 57.38
14 0.2 0 13.8 1.2 9.1 7.1 33 31.4
Mean 1.643 1.348 9.473 1.256 6.12 8.008 32.533 167.1 195.2
SD 1.238 1.267 3.354 0.389 5.294 8.617 13.281
SEM 0.553 0.567 1.500 0.174 2.367 3.853 5.939
PEPTIDES Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
9 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0
11 0 0 0 0 0 0 0
12 0 0 0 0 0 0 0
13 NOT DONE
14 NOT DONE
Mean 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0
SEM 0 0 0 0 0 0 0
Data for IL12 secretion in PBMC (IL12 pg/ml /ngm stimulant / million cells) Control (6)
GPS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
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15 11.6 9.45 27.7 7.9 15 16.5 0.18 88.15
16 64 43 131 13.7 42 46 1.9 339.7
17 31.2 18.5 44 10.2 15.5 21.1 0.038 140.5
18 0 0 2.08 4.44 6.66 20 15 33.18
19 0 0 8.44 2.04 3.77 6.85 8 21.1
20 0 12.45 13.33 4.16 8.88 10.71 15 49.53
Mean 17.8 13.9 37.758 7.073 15.301 20.193 6.686 672.16 40.118
SD 25.701 15.976 48.090 4.361 13.869 13.772 7.062
SEM 11.494 7.145 21.506 1.950 6.202 6.159 3.158
GLYCANS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
15 10.4 11.2 16.1 4 6.8 14.5 0.23 63
16 38.2 18.5 172 26 84 86 0.27 424.7
17 28 19 68 11.1 14.2 26.2 0.53 166.5
18 7 5.45 27.7 4.16 5.55 12.85 14 62.71
19 7 4.36 69.4 22.2 26.6 42.85 20 172.41
20 11.2 16.2 11.36 17.22 5.88 12.44 17.85 74.3
Mean 16.966 12.451 60.76 14.113 23.838 32.473 8.813 963.62 52.88
SD 13.020 6.474 60.048 9.238 30.552 28.710 9.476
SEM 5.822 2.895 26.854 4.131 13.663 12.839 4.237
PEPTIDES Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
15 3.68 3.68 5.6 6.24 3.3 4 0
16 3.36 2.7 2.7 1.6 3 2.7 0
17 1.22 2.6 2.5 1.7 1.5 1.1 0
18 0 0 0 0 0 0 0
19 0 0 0 0 0 0 0
20 0 0 0 0 0 0 0
Mean 1.376 1.496 1.8 1.59 1.3 1.3 0
SD 1.729 1.682 2.256 2.417 1.549 1.694 0
SEM 0.773 0.752 1.009 1.081 0.692 0.757 0
Data for IL4 secretion in PBMC -  (IL4 pg/ml /ngm stimulant / million cells) MNCC (8)
GPS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
1 0 0 0 0 0 0 60 0
2 0.8 2.5 2.7 0.5 0.8 1.4 150 8.7
94
3 0 5.09 10.5 5.5 12.6 16.2 80 49.89
4 1.4 2.3 5 0.5 0.8 1.4 110 11.4
5 0.8 0.72 1.6 0.4 0 0 20 3.52
6 6.6 7.2 10.5 6.1 9.7 17.1 42.4 57.2
7 5.5 5.3 11.3 9.7 17.64 2.5 111 51.94
8 3.8 1.1 17.2 3.8 5.7 7.1 30 38.7
Mean 2.362 3.026 7.35 3.312 5.905 5.712 75.425 221.35 603.4
SD 2.586 2.559 5.936 3.563 6.748 7.115 45.524
SEM 0.977 0.967 2.243 1.346 2.550 2.689 17.206
GLYCANS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
1 0.6 2.5 3.8 1.6 3.3 4.5 75 16.3
2 1.4 2 3.8 1 3.7 20 160 31.9
3 0 56 2.72 55.5 77.7 145.7 75.6 337.62
4 4.6 4.7 15.5 3.3 6.2 8.5 105 42.8
5 3.4 3.4 2.7 1.1 2.4 3.4 25 16.4
6 6.8 5.6 5 5.5 8.8 14 49.2 94.9
7 2.9 5.3 15.4 8.4 11.32 20.5 141 204.82
8 2 5.6 15 3 9.3 13.7 50 98.6
Mean 2.712 10.637 7.99 9.925 15.34 28.787 85.1 843.34 680.8
SD 2.230 18.382 6.097 18.584 25.398 47.669 46.989
SEM 0.843 6.947 2.304 7.024 9.599 18.017 17.760
PEPTIDES Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
1 0 0 0 0 0 0 0
2 1.4 2 3.8 1 3.7 20 160
3 0 0.09 0.056 0 0 0 0
4 0 0 0 0 0 0 0
5 0 0 0 0.024 0 0 0
6 NOT DONE
7 NOT DONE
8 NOT DONE
Mean 0.28 0.418 0.771 0.204 0.74 4 32
SD 0.626 0.885 1.693 0.444 1.654 8.944 71.554
SEM 0.313 0.442 0.846 0.222 0.827 4.472 35.777
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Data for IL4 secretion in PBMC (IL4 pg/ml /ngm stimulant / million cells) SCG(6)
GPS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
9 10.4 7.6 55 52.7 88.8 92.8 80 307.3
10 0.6 0.54 7.7 8.8 16.6 22.8 92.4 57.04
11 3.4 20 61 9.4 17.7 21.4 80 132.9
12 13 4.36 55 8.8 15.5 30 92 126.66
13 2 1.8 6.6 5.5 4.2 21.4 108 41.5
14 0 3.6 1.1 6.6 11.5 6 76 28.8
Mean 4.9 6.316 31.066 15.3 25.716 32.4 88.066 694.2 528.4
SD 5.459 7.125 28.580 18.383 31.293 30.610 11.893
SEM 2.441 3.186 12.781 8.221 13.994 13.689 5.319
GLYCANS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
9 30 36 88 10.5 16.6 19.42 77 200.52
10 0 0 0 42.7 91.1 108 88.6 241.8
11 0 36 127.7 23.8 47.7 62.8 72.4 298
12 85 5.09 209 43.3 88.3 112.2 86.8 542.89
13 0 3.2 13.8 8 10.2 20.7 108 55.9
14 0 2.7 0 7.2 10 8.5 80 28.4
Mean 19.166 13.831 73.083 22.583 43.983 55.27 85.466 1367.51 512.8
SD 34.411 17.248 84.706 16.915 38.062 46.359 12.582
SEM 15.389 7.7137 37.881 7.564 17.022 20.732 5.627
PEPTIDES Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
9 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0
11 0 0 0 0 0 0 0
12 0 0 0 0 0 0 0
13 NOT DONE
14 NOT DONE
Mean 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0
SEM 0 0 0 0 0 0 0
Data for IL4 secretion in PBMC (IL4 pg/ml /ngm stimulant / million cells)
Control 
(3)
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GPS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
15 0 0 0 0.43 0.43 1.1 0.1 1.96
16 0 0 0 0.4 0.4 2.2 0 3
17 0 0 0 0 0.44 1.14 0 1.58
18 NOT DONE
19 NOT DONE
20 NOT DONE
Mean 0 0 0 0.276 0.423 1.48 0.1 6.54 0.1
SD 0 0 0 0.240 0.020 0.623 0.0
SEM 0 0 0 0.169 0.014 0.441 0.0
GLYCANS Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
15 0 0 0 0 0 2.21 0.09 2.21
16 0 0 0 0.4 0.4 2.2 0 3
17 0.4 0 2.2 0.88 2.68 2.28 0.02 8.44
18 NOT DONE
19 NOT DONE
20 NOT DONE
Mean 0.133 0 0.733 0.426 1.026 2.23 0.036 13.65 0.11
SD 0.230 0 1.270 0.440 1.445 0.043 0.047
SEM 0.163 0 0.898 0.311 1.022 0.030 0.033
PEPTIDES Patients 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa LLGP 50-13kDa LLGP
15 0.016 0.032 0.016 0.032 0.048 0.064 0.03
16 0 0 0 0.016 0.016 0.064 0
17 0.016 0.06 0.04 0.032 0.032 0.048 0
18 0 0 0 0 0 0 0
19 0 0 0 0 0 0 0
20 0 0 0 0 0 0 0
Mean 0.010 0.030 0.018 0.026 0.032 0.058 0.01
SD 0.009 0.030 0.020 0.009 0.016 0.009 0.017
SEM 0.006 0.021 0.014 0.006 0.011 0.006 0.012
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MNCC(8) – Glycoprotein (GP) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (MNCC) (GLYCOPROTEIN) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
1 4.35 86 83 83 52 53 211 568
2 1.8 80 56 188 37 80 114 555
3 2.05 122 98.18 52.22 36.66 186.66 105.71 601.43
4 2.05 166 43 77.77 28.88 0 108.5 424.15
5 0 80 0 105 1.1 42.2 357 585.3
6 1.6 56 36 111 26 128 108 465
7 0.24 8 8.7 26 8.4 13 13 77.1
8 0.35 11.2 9 21 6.2 12.4 15 74.8
Mean 1.555 76.15 41.735 82.9987 24.53 64.4075 129.0262 3350.78 12.44
SD 1.4123 52.8756 35.9195 53.9321 17.8223 64.7544 111.3480
SEM 0.5338 19.9851 13.5763 20.3844 6.73621 24.4748 42.0855
MNCC(8) – Glycans (GL) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (MNCC) (GLYCANS) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
1 7.5 176 94.54 583 222 266 277 1618.54
2 3.1 116 83.63 333 64 75.5 151 823.13
3 2.85 166 74.54 316 103.33 193.33 260 1113.2
4 2.85 100 40 55.55 103.33 134.28 145.71 578.87
5 1.65 50 34.54 11 5.5 82 128 311.04
6 5.64 24 17.4 40 15 71 34 201.4
7 0.58 12.8 13.8 42.2 12 24 28.5 133.3
8 0.39 6.4 5.4 40 7.5 13 17 89.3
Mean 3.07 81.4 45.4812 177.5937 66.5825 107.3887 130.1512 4868.78 24.56
SD 2.4414 67.8876 34.3407 209.2521 75.3314 86.2845 101.0571
SEM 0.9227 25.6591 12.9795 79.0898 28.4726 32.6124 38.1960
MNCC(5) – Peptides (Pp) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (MNCC) (PEPTIDES) Total
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Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
1 0 0.8 0.96 1.6 3.6 0 3.2 10.16
2 0 1.44 2.24 1.52 0 0.96 1.68 7.84
3 0 1.28 1.6 0.4 0.4 2.32 2.32 8.32
4 0 0.4 1.44 0.8 0 1.52 0 4.16
5 0 0.16 0 0 0 0 0 0.16
6 NOT DONE
7 NOT DONE
8 NOT DONE
Mean 0 0.816 1.248 0.864 0.8 0.96 1.44 30.64 0
SD 0 0.5496 0.8344 0.6960 1.5748 1.0007 1.4209
SEM 0 0.2748 0.4172 0.3480 0.7874 0.5003 0.7104
SCG(6) – Glycoprotein (GP) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (SCG) (GLYCOPROTEIN) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
9 2.2 52 96 155 32 97 65 497
10 0.49 19.6 21 47 9.5 30 33 160.1
11 3.9 156 145 411 34 60 88 894
12 10.4 416 29 0 14 0 28 487
13 1.85 24 21.8 66.6 17.7 82.22 68.57 280.89
14 0.9 23 13.8 31 6.2 12.4 22.8 109.2
Mean 3.29 115.1 54.4333 118.4333 18.9 46.9366 50.895 2428.19 19.74
SD 3.6807 156.2671 53.6856 152.5731 11.6165 38.9989 26.5400
SEM 1.6460 69.8847 24.0089 68.2327 5.1950 17.4408 11.8690
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SCG(6) – Glycans (GL) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (SCG) (GLYCANS) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
9 3.8 52 100 255 53 131 105 696
10 0.78 25.2 15 177 26 38.6 68.5 350.3
11 4.1 144 158 455 110 200 205 1272
12 4.2 34 83 211 86.66 166 231 811.66
13 2.25 38 36.36 122 22.2 86.66 120 425.22
14 1.16 19.2 18.18 57.7 11.5 22.2 66.2 194.98
Mean 2.715 52.0666 68.4233 212.95 51.56 107.41 132.6166 3750.16 16.29
SD 1.5283 46.4285 55.9286 137.1328 39.4193 70.6941 69.8034
SEM 0.6834 20.7634 25.0120 61.3276 17.6288 31.6153 31.2170
SCG(4) – Peptides (Pp) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (SCG) (PEPTIDES) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
9 0 0.064 0.64 1.21 0.27 0.32 0.35 2.854
10 0 0.54 0.43 0.48 0.76 0.56 0.36 3.13
11 0 0 0 0 0 0 0 0
12 0 0 0.8 0 0 0 0 0.8
13   NOT DONE   
14   NOT DONE   
Mean 0 0.151 0.4675 0.4225 0.2575 0.22 0.1775 6.784 0
SD 0 0.2610 0.3465 0.5716 0.3583 0.2722 0.205
SEM 0 0.1305 0.1732 0.2858 0.1791 0.1361 0.1025
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CONTROL(6) – Glycoprotein (GP) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (CONTROL) (GLYCOPROTEIN) Total
Patients LLGP   50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
15 0.108 7.652 1.568 5.876 4.572 3.788 4.048 27.504
16 0.096 7.388 3.124 6.856 4.188 7.616 8 37.172
17 0.105 8.888 1.956 3.91 3.464 4.8 8.888 31.906
18 0.27 22.6 21.2 3.94 7 17.5 5 77.24
19 0.36 25.6 16 5.2 13.7 19.1 26.8 106.4
20 0.37 14 15 4.2 10.2 18.2 28 89.6
Mean 0.2181 14.3546 9.808 4.997 7.1873 11.834 13.456 369.822 1.405
SD 0.1309 7.9738 8.5942 1.2003 4.0305 7.1753 10.9566
SEM 0.0585 3.5660 3.8434 0.5367 1.8025 3.2089 4.8999
CONTROL(6) – Glycans (GL) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (CONTROL) (GLYCANS) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
15 1.394 24.4 19.01 64.56 33.57 15.06 37.08 193.68
16 1.5 18 38.18 147.22 36.66 51.1 68.56 359.72
17 1.09 12 16.36 13.88 15.55 25.55 78.56 161.9
18 0.22 33 18 61.66 15.66 31.33 22 181.65
19 0.52 30.8 33.45 88 21.3 36.8 62.85 273.2
20 0.24 36.4 24.7 75 11.7 34.2 42.28 220.52
Mean 0.8273 25.7666 24.95 75.0533 22.4066 32.34 51.8883 1389.68 4.964
SD 0.5746 9.4067 8.9968 43.3758 10.3553 12.0084 21.5146
SEM 0.2569 4.2068 4.0235 19.3982 4.6310 5.3703 9.6216
101
CONTROL(6) – Peptides (Pp) NITRIC OXIDE
nmoles nitrite / ml / ngm protein / million cells (CONTROL) (PEPTIDES) Total
Patients LLGP 50kDa 38kDa 24kDa 18kDa 14kDa 13kDa 50-13kDa LLGP
15 0.15 0.12 0.19 0.63 0.525 0 0.135 1.6
16 0.14 0.272 0.4 0 0.592 0.56 0.672 2.496
17 0.149 0.172 0.204 0.423 0.94 0.11 0.94 2.789
18 0.27 0 0 0 0 0 0 0
19 0.36 0 28 24 20 0 52 124
20 0.37 0 0 0 8 0 0 8
Mean 0.2398 0.094 4.799 4.1755 5.0095 0.1116 8.9578 287.885 1.439
SD 0.1082 0.1139 11.3671 9.7156 7.9364 0.2240 21.0897
SEM 0.0484 0.0509 5.0835 4.3449 3.5493 0.1001 9.43164
GPS – Glyco Proteins LLGP – Lentil Lectin Glyco Protein MNCC – Multiple Neuro Cysticercosis SCG – Solitary Cysticercal Granuloma 
IL – Interleukins  
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